551 related articles for article (PubMed ID: 31560828)
1. Ovarian cancer: Current status and strategies for improving therapeutic outcomes.
Chandra A; Pius C; Nabeel M; Nair M; Vishwanatha JK; Ahmad S; Basha R
Cancer Med; 2019 Nov; 8(16):7018-7031. PubMed ID: 31560828
[TBL] [Abstract][Full Text] [Related]
2. [Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].
Gallardo-Rincón D; Cantú-de-León D; Alanís-López P; Alvarez-Avitia MA; Bañuelos-Flores J; Herbert-Núñez GS; Oñate-Ocaña LF; Pérez-Montiel MD; Rodríguez-Trejo A; Ruvalcaba-Limón E; Serrano-Olvera A; Ortega-Rojo A; Cortés-Esteban P; Erazo-Valle A; Gerson-Cwilich R; De-la-Garza-Salazar J; Green-Renner D; León-Rodríguez E; Morales-Vásquez F; Poveda-Velasco A; Aguilar-Ponce JL; Alva-López LF; Alvarado-Aguilar S; Alvarado-Cabrero I; Aquino-Mendoza CA; Aranda-Flores CE; Bandera-Delgado A; Barragán-Curiel E; Barrón-Rodríguez P; Brom-Valladares R; Cabrera-Galeana PA; Calderillo-Ruiz G; Camacho-Gutiérrez S; Capdeville-García D; Cárdenas-Sánchez J; Carlón-Zárate E; Carrillo-Garibaldi O; Castorena-Roji G; Cervantes-Sánchez G; Coronel-Martínez JA; Chanona-Vilchis JG; Díaz-Hernández V; Escudero-de-los Ríos P; Garibay-Cerdenares O; Gómez-García E; Herrera-Montalvo LA; Hinojosa-García LM; Isla-Ortiz D; Jiménez-López J; Lavín-Lozano AJ; Limón-Rodriguez JA; López-Basave HN; López-García SC; Maffuz-Aziz A; Martínez-Cedillo J; Martínez-López DM; Medina-Castro JM; Melo-Martínez C; Méndez-Herrera C; Montalvo-Esquivel G; Morales-Palomares MA; Morán-Mendoza A; Morgan-Villela G; Mota-García A; Muñoz-González DE; Ochoa-Carrillo FJ; Pérez-Amador M; Recinos-Money E; Rivera-Rivera S; Robles Flores JU; Rojas-Castillo E; Rojas-Marín C; Salas-Gonzáles E; Sámano-Nateras L; Santibañez-Andrade M; Santillán-Gómez A; Silva-García A; Silva JA; Solorza-Luna G; Tabarez-Ortiz AR; Talamás-Rohana P; Tirado-Gómez LL; Torres-Lobatón A; Quijano-Castro F
Rev Invest Clin; 2011; 63(6):665-702. PubMed ID: 23650680
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
4. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
5. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Tavares V; Marques IS; Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339123
[TBL] [Abstract][Full Text] [Related]
6. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer-A Systematic Review.
Bachmann C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001616
[TBL] [Abstract][Full Text] [Related]
7. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.
Phillips-Chavez C; Watson M; Coward J; Schloss J
Eur J Clin Pharmacol; 2020 Aug; 76(8):1059-1074. PubMed ID: 32440721
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
9. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Lliberos C; Richardson G; Papa A
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785992
[TBL] [Abstract][Full Text] [Related]
11. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah GA; Kampan NC; Chew KT; Mohd Mokhtar N; Md Zin RR; Shafiee MNB; Abd Aziz NHB
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768291
[TBL] [Abstract][Full Text] [Related]
12. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
Baumann KH; Wagner U; du Bois A
Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
[TBL] [Abstract][Full Text] [Related]
13. Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer.
Sheng R; Li X; Wang Z; Wang X
Cancer Lett; 2020 Mar; 473():139-147. PubMed ID: 31904484
[TBL] [Abstract][Full Text] [Related]
14. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
15. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
17. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
19. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.
Marchetti C; De Felice F; Perniola G; Lecce F; Vertechy L; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Curr Probl Cancer; 2018; 42(2):235-240. PubMed ID: 29433824
[TBL] [Abstract][Full Text] [Related]
20. Molecular features as promising biomarkers in ovarian cancer.
Bukłaho PA; Kiśluk J; Wasilewska N; Nikliński J
Adv Clin Exp Med; 2023 Sep; 32(9):1029-1040. PubMed ID: 36920264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
